FDA accepts Teva's hayfever drug for review
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for review Teva's NDA for, BDP Nasal HFA (beclomethasone dipropionate hydrofluoroalkane), a nasal aerosol corticosteroid for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).